News

China green-lights domestic Ebola shot for clinical trials

China has approved a locally developed Ebola vaccine from its Academy of Military Medical Sciences for clinical trials, state news agency Xinhua said Thursday.

GSK shingles candidate hits its mark in hefty Phase III study

More than four years ago, GlaxoSmithKline began a Phase III study of a shingles candidate it hoped would eventually mount a challenge to Merck's Zostavax. Now, that candidate is one step closer after hitting its primary endpoint in that trial.

Finnish scientists ID link between GSK's swine flu vaccine and narcolepsy

A team from Finland has for the first time confirmed a link between GlaxoSmithKline's swine flu vaccine, Pandemrix, and narcolepsy.

Study: Universal dengue vaccine may be possible thanks to antibody discovery

So far, Sanofi's dengue candidate, the furthest along in the clinic, has struggled to ward off all four dengue viruses. But now, researchers have discovered new antibodies that could lead to a vaccine that does just that.

Baxter backs away from vaccines with Vero tech sale to Nanotherapeutics

Baxter, prepping for a biopharma spinoff, has already revealed that vaccines won't figure into its plans going forward. And Monday, it took it second step to exit the space with a sale of its Vero technology and related assets.

Sanofi adds another quadrivalent to its quiver with Fluzone Intradermal approval

Last year, Sanofi's fourth-quarter flu vaccine sales soared on the introduction of a quadrivalent contender, surging more than 94%. Now, looking to keep that growth coming, the company is adding another four-strain shot to the mix.

New financing helps Anergis take allergy vaccine to Phase III

Strong Phase IIb data for Anergis' birch allergy vaccine, AllerT, was enough to convince all the company's existing investors to come back for a Series B financing round--and some new ones, too. And now, the company has rounded up the cash to take the candidate into Phase III.

Merck wins FDA approval for Gardasil follow-up

Merck's Gardasil follow-up is here, meaning blockbuster sales figures are likely on the way. But the bad news is that they'll come at the expense of the world's second-best-selling shot.

Ebola vaccine makers Merck, GSK, J&J get legal protections in U.S. thanks to HHS declaration

Ebola vaccine developers now have a little less to worry about thanks to a Tuesday announcement from the U.S. Department of Health and Human Services. HHS will provide liability protections for the companies scrambling to develop Ebola vaccines in response to the current outbreak in West Africa, it said.

Merck Vaccines president Gerberding leaving post for EVP role

Julie Gerberding, president of Merck's vaccines unit, will be moving on come mid-December for a new role as executive vice president for strategic communications, global public policy and population health, the company announced Wednesday.

Amgen tests T-Vec's combo potential in trial with Merck's Keytruda

Amgen's cancer vaccine candidate may be awaiting FDA and EMA approval as a melanoma monotherapy, but like many of its peers, it's also looking to explore its prospect's potential as part of an immunotherapy duo, and now it's kicked off a trial combining its treatment with Merck's anti-PD-1 therapy that should help it do just that.

PaxVax meets primary endpoints in PhIII cholera vaccine trial

Right now, there is no FDA-approved cholera vaccine for U.S. travelers heading to high-risk countries. A California company hopes to change that soon: On Monday, PaxVax said it planned to submit a Biologics License Application for its oral single-dose candidate in mid-2015.

Powdered measles vaccine, safe in PhI, could aid vaccination in developing world

A powdered measles vaccine could mean a cheaper option for the developing world that eliminates storage, contamination and waste challenges. And researchers now have one that looks safe in Phase I.

Universal flu vaccine developer BiondVax mulling IPO: Globes

Israel's BiondVax Pharmaceuticals, whose universal flu vaccine candidate has so far undergone a successful Phase II trial and is set for another next year, is thinking about a Wall Street IPO, according to Israeli newspaper Globes.

Wash. U. breast cancer vaccine looks promising in early trial

In the troubled cancer vaccine field, where experimental jabs seem to be dropping like flies, a breast cancer vaccine developed at the Washington University School of Medicine in St. Louis has shown promising results in an early clinical trial.

Merck, NewLink Ebola vaccine trial shows no serious side effects so far

Just days after GlaxoSmithKline and the NIH's National Instite of Allergy and Infectious Diseases announced Phase I success for their investigative Ebola vaccine, Merck and NewLink Genetics have their own positive news to report.

GSK, NIH gear up for Ebola vaccine trial expansion after success in PhI

The race for an Ebola vaccine is ramping up with positive Phase I data from an experimental vaccine made by GlaxoSmithKline and the NIH's National Institute of Allergy and Infectious Diseases. And thanks to those results, larger trials could be on the way soon.

UPDATED: Novartis' Fluad off the hook in Italy following 19 deaths

After last week partially banning Novartis' Fluad, Italian officials now say tests on the flu vaccine show the product is safe.

UPDATED: NewLink, Merck sign Ebola vaccine licensing pact

To scale up production of its Ebola vaccine, NewLink Genetics is going to need some manufacturing help. And for that, it's turning to vaccine giant Merck.

Themis, Institut Pasteur expand collaboration on solid PhI Chikungunya results

Themis Bioscience and the Institut Pasteur have good news to report from a Phase I trial of their Chikungunya fever vaccine candidate. And the pair thinks its successful results just might lead to advances in other diseases, too.